SCHEDULE: Deep Track Capital Discloses 5.54% Stake in Definium Therapeutics

Deep Track Capital, LP and affiliates reported a 5.54% beneficial ownership stake in Definium Therapeutics, Inc. as of December 31, 2025.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 5,676,540 Common Shares of Definium Therapeutics, Inc.
• This ownership represents 5.54% of the outstanding Common Shares.
• The calculation of beneficial ownership is based on 102,509,279 shares, which includes 98,509,279 Common Stock outstanding as of October 31, 2025, and 4,000,000 Common Stock convertible from Pre-Funded Warrants.
• The 4,000,000 Pre-Funded Warrants are exercisable into common shares but are subject to a 9.99% maximum percentage exercise limitation, preventing the holder from exceeding this threshold post-exercise.
• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, indicating a significant, passive institutional investment in Definium Therapeutics, which can be interpreted as a vote of confidence without implying activist intent.

Positives

• A significant institutional investor, Deep Track Capital, maintains a substantial stake, potentially indicating confidence in Definium Therapeutics' long-term prospects.
• The passive nature of the filing (Schedule 13G) suggests the investment is not for control purposes, reducing immediate activist pressure on management.

Risks

• The 9.99% maximum percentage exercise limitation on Pre-Funded Warrants could restrict Deep Track Capital's ability to increase its stake beyond this threshold without triggering additional reporting requirements or potential dilution concerns if other warrants are exercised.

Future Outlook

Not applicable, as this Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's business outlook.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can be a signal of investor confidence or strategic positioning within the biotechnology sector. Deep Track Capital's specialized focus on biotechnology suggests a targeted interest in Definium Therapeutics' potential, aligning with broader trends of specialized funds investing in specific high-growth industries.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder; potential positive sentiment from institutional backing.
• Management: Awareness of a substantial, passive institutional investor on the shareholder register.

Key Dates

Recommendation

The filing indicates a significant, passive institutional stake by Deep Track Capital in Definium Therapeutics. While this suggests a degree of confidence from a specialized investor, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a 'buy' or 'sell' recommendation. The investment is a disclosure of existing ownership, making 'hold' the most appropriate recommendation based solely on this filing.

Keywords

Definium Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, Common Shares, Pre-Funded Warrants, Institutional Investor, Biotechnology